By Tracy Waller, Esq., MPH
“If it’s COVID, Paxlovid.” Or is it? Pfizer launched its most recent commercial for Paxlovid in February 2023 and has gone full throttle into its advertisement of the drug. Pfizer first received Emergency Use Authorization (“EUA”) for Paxlovid in December 2021 and then received a revised EUA in February 2023. The commercial touts the drug as a “miracle” drug of sorts. On November 6, 2022, the Office of Veterans Affairs released a study showing that Paxlovid can reduce the risk of symptoms of long COVID. Pfizer includes in its commercial for the drug, as required, that certain classes of people are excluded from taking Paxlovid based on negative drug interactions; however, the gravity of the number of people who are ineligible to take the drug is not readily apparent and leaves large swaths of the United States’ (“US”) and global populations without access to this life-saving drug. The lack of access to Paxlovid for the people most vulnerable to COVID-19- the elderly, people with disabilities, and other immunocompromised people – emphasizes the need for pharmaceutical companies to focus on developing treatment options that meet the needs of so many of those left behind.
Authored by: Tracy Waller, Esq., MPH
As a result of the COVID-19 public health crisis, children are being forced to shoulder an incomprehensible burden of loss. Many children have experienced health issues due to COVID-19 infections or long COVID-19 symptoms. They have also encountered a loss of innocence and protection, as they shoulder the weight of a parent coping with long COVID-19—or worse, the death of a parent or primary caregiver from COVID-19. This loss disproportionately affects young children and children with developmental disabilities because of the increased reliance on their caregivers.
Authored by: Tracy Waller, Esq., MPH; With contribution by: Tiffany Banks, MSW, LCSW
Schools that do not require masking fail to meet the needs of children with disabilities
Based on the rise of the delta variant of COVID-19, and the increasing number of breakthrough infections, the Centers for Disease Control and Prevention (CDC) revised its masking guidance on July 27, 2021. The CDC continues to recommend that people ages 2 and older and those who are not fully vaccinated should wear a mask in indoor public places. In addition, the CDC guidance recommends that fully vaccinated people should wear a mask indoors in public in areas of substantial or high transmission.